NasdaqGS - Nasdaq Real Time Price USD

Gilead Sciences, Inc. (GILD)

66.16

-0.77

(-1.15%)

At close: April 18 at 4:00 PM EDT

65.94

-0.22

(-0.33%)

Pre-Market: 4:00 AM EDT

US FDA mandates label updates on CAR-T cancer therapies

The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.

Reuters 9 hours ago

NVS

JNJ
+0.67%
GILD
-1.15%
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.

Zacks 10 hours ago

GILD
-1.15%
Gilead Sciences Publishes 2023 ESG Impact Report

NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's ...

ACCESSWIRE 14 hours ago

GILD
-1.15%
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 18 hours ago

GILD
-1.15%
BIIB
-0.85%
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA

Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon.

PR Newswire 2 days ago

GILD
-1.15%
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.

Zacks 2 days ago

XLO

GILD
-1.15%
FGEN
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Zacks 2 days ago

GILD
-1.15%
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?

Dividend stocks can be a smart way to ride out market volatility.

Motley Fool 3 days ago

COMP

KHC

WBA
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA

Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) in conjunction with the World Hepatitis Summit ("Summit"). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit"

PR Newswire 4 days ago

GILD
-1.15%
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG

Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis C, hepatitis B, and hepatitis D in conjunction with the World Hepatitis Summit ("Summit"). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon from 9

PR Newswire 4 days ago

GILD
-1.15%
Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know

In the most recent trading session, Gilead Sciences (GILD) closed at $68.07, indicating a -0.84% shift from the previous trading day.

Zacks 6 days ago

GILD
-1.15%
12 Best Depressed Stocks To Buy in 2024

In this article, we will take a detailed look at the 12 Best Depressed Stocks To Buy in 2024. For a quick overview of the 5 such stocks, read our article 5 Best Depressed Stocks To Buy in 2024. JPMorgan Chief Jamie Dimon, in his latest letter to shareholders, has warned that the real odds of soft landing a quite […]

Insider Monkey 8 days ago

LW

SAGE

ACLS
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Gilead Sciences (GILD) closed at $69.94, indicating a +0.75% shift from the previous trading day.

Zacks 9 days ago

GILD
-1.15%
3 Stocks at 52-Week Lows Poised for a Powerful Rebound

With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential. While exercising caution is prudent, given valid underperformance reasons exist, comparing current metrics to historical peaks could reveal bargain stocks at 52-week lows. Understanding the drivers of underperformance provides insight into rebound likelihood. Since recovery duration may mirror price

InvestorPlace 9 days ago

SBUX

VALE

GILD
-1.15%
11 Best Biotech ETFs To Buy

In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]

Insider Monkey 9 days ago

AMGN
-0.50%
NTRA

NBIX
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

FOSTER CITY, Calif., April 08, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2024 financial results and provide a business update.

Business Wire 10 days ago

GILD
-1.15%
3 No-Brainer Dividend Stocks to Buy in April

Income investors will find a lot to like about these stocks.

Motley Fool 12 days ago

PFE
-0.12%
ABBV
+0.25%
GILD
-1.15%
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows

All of these stocks pay generous dividends that income investors will appreciate.

Motley Fool 13 days ago

SBUX

GILD
-1.15%
BCE
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks 15 days ago

GILD
-1.15%
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

Gilead Sciences (GILD) closed at $72.09 in the latest trading session, marking a -1.08% move from the prior day.

Zacks 16 days ago

GILD
-1.15%

Performance Overview

Return	GILD	S&P 500
YTD	-17.49%	+5.06%
1-Year	-17.78%	+20.71%
3-Year	+11.91%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gilead Sciences, Inc. (GILD)

US FDA mandates label updates on CAR-T cancer therapies

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Gilead Sciences Publishes 2023 ESG Impact Report

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG

Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know

12 Best Depressed Stocks To Buy in 2024

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

3 Stocks at 52-Week Lows Poised for a Powerful Rebound

11 Best Biotech ETFs To Buy

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

3 No-Brainer Dividend Stocks to Buy in April

Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

Performance Overview